News coverage about Cardiovascular Systems (NASDAQ:CSII) has trended somewhat positive on Monday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cardiovascular Systems earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 46.8542876110636 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Several research analysts have commented on the stock. BidaskClub raised shares of Cardiovascular Systems from a “hold” rating to a “buy” rating in a research note on Friday, June 9th. Bank of America Corporation downgraded shares of Cardiovascular Systems from a “neutral” rating to an “underperform” rating in a research note on Wednesday, June 21st. Needham & Company LLC reissued a “buy” rating and set a $37.00 price target (up from $32.00) on shares of Cardiovascular Systems in a research note on Friday, July 14th. Finally, Zacks Investment Research downgraded shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Three analysts have rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $33.83.
Cardiovascular Systems (CSII) opened at 30.45 on Monday. The company has a 50 day moving average of $30.19 and a 200 day moving average of $30.13. Cardiovascular Systems has a 52 week low of $21.29 and a 52 week high of $33.11. The stock’s market capitalization is $1.00 billion.
Cardiovascular Systems (NASDAQ:CSII) last issued its quarterly earnings results on Wednesday, August 2nd. The medical device company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.07. The company had revenue of $52.90 million during the quarter, compared to the consensus estimate of $51.98 million. Cardiovascular Systems had a positive return on equity of 0.88% and a negative net margin of 0.87%. Cardiovascular Systems’s revenue was up 9.1% on a year-over-year basis. During the same period last year, the company earned ($0.15) earnings per share. Equities analysts expect that Cardiovascular Systems will post $0.01 EPS for the current fiscal year.
In other Cardiovascular Systems news, Director Edward M. Brown sold 20,000 shares of the stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $29.16, for a total value of $583,200.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Alexander Rosenstein sold 979 shares of the stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $30.71, for a total value of $30,065.09. Following the completion of the sale, the general counsel now owns 52,296 shares in the company, valued at approximately $1,606,010.16. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 51,065 shares of company stock valued at $1,514,031. 3.60% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This piece was reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://transcriptdaily.com/2017/09/18/cardiovascular-systems-csii-earning-somewhat-favorable-news-coverage-study-shows.html.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.